Table 1 Characteristics of elderly and non-elderly NAFLD patients were compared using1:3 sex-matched analysis

median (IQR); n (%)

(n = 175)

(n = 525)

Age (year)

64 (62–67)

46 (36–54)

Female

102 (58.3%)

306 (58.3%)

Weight (kg)

69.45 (62.08–78.13)

78.5 (68.1–97.3)

Height (m)

1.6 (1.54–1.67)

1.6 (1.6–1.7)

BMI (kg/m²)

27.19 (24.73–30.34)

29.62 (26.45–35)

BMI ≥ 25 (kg/m²)

126 (72%)

443 (84.4%)

Waist circumference (cm)

92.05 (81.75–99.63)

91.2 (78–102.5)

Hip circumference (cm)

97 (87.75–104)

100 (88–108)

Central obesity

126 (85.1%)

350 (85.6%)

Diabetes

122 (69.7%)

237 (45.1%)

Hypertension

122 (74.8%)

189 (43.8%)

Dyslipidemia

148 (84.6%)

374 (71.2%)

Albumin (g/L)

43 (41–46)

44 (41–46)

ALT (U/L)

55 (38–94)

61 (37–90)

AST (U/L)

43 (26–66)

40 (29.8–68)

ALP (U/L)

69 (53.25–91)

67 (48.5–91.5)

GGT (U/L)

53 (37–87)

50 (31–86)

HbA1c (%)

6.65 (5.9–7.33)

6.1 (5.6–7.2)

Total cholesterol (mmol/L)

4.4 (3.5–5.33)

5 (4.3–5.7)

LDL cholesterol (mmol/L)

2.3 (1.79–3.25)

3 (2.43–3.7)

HDL cholesterol (mmol/L)

1.25 (1.1–1.44)

1.2 (1.01–1.5)

Triglycerides (mmol/L)

1.4 (1.1–1.8)

1.4 (1.1–1.9)

Hemoglobin (g/dL)

14.1 (13.4–15.08)

13.9 (13.1–15.1)

Platelet (10⁹/L)

227.5 (177.5–280.75)

251 (202–297)

WBC (10⁹/L)

6.57 (5.6–8)

7.3 (5.9–8.8)

NAFLD Activity Score (NAS)

4 (3–5)

4 (3–5)

NAS ≥ 5

58 (33.1%)

221 (40.2%)

NASH

118 (67.4%)

335 (63.8%)

Significant fibrosis (≥F2): histopathology

86 (49.1%)

138 (26.3%)

Advanced fibrosis (≥F3): histopathology

62 (35.4%)

70 (13.3%)

Cirrhosis

27 (15.4%)

25 (4.8%)

NAFLD fibrosis score (NFS)^a

−0.75 (1.49)

−1.91 (1.88)

APRI score^a

1.18 (2.02)

0.74 (1.55)

FIB-4 score^a

3.88 (6.72)

1.58 (3.93)